IDiyas

For the Inventor, By the Inventor

Brookline, MA, United States of America

Francesc Xavier Fradera Llinas

USPTO Granted Patents = 11

 

Average Co-Inventor Count = 15.6

ph-index = 1

Forward Citations = 9(Granted Patents)


Location History:

  • Boston, MA (US) (2019)
  • Brookline, MA (US) (2014 - 2020)

Company Filing History:

goldMedal11 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 2014-2020

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):
1. 10544147 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2020-01-28),
2. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),
3. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),
4. 10086000 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2018-10-02),
5. 9938281 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-04-10),
6. 9730940 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2017-08-15),
7. 9682978 - 2,6,7 substituted purines as HDM2 inhibitors (2017-06-20),
8. 9637493 - Substituted pyrrolopyrimidines as HDM2 inhibitors (2017-05-02),
9. 9540377 - 2,6,7,8 substituted purines as HDM2 inhibitors (2017-01-10),
10. 8962611 - Substituted imidazopyridines as HDM2 inhibitors (2015-02-24),
11. 8846657 - Substituted imidazopyridines as HDM2 inhibitors (2014-09-30),

Title: Francesc Xavier Fradera Llinas: Pioneer in Innovation and Technology

Introduction:

Francesc Xavier Fradera Llinas, a distinguished inventor based in Brookline, MA, US, is celebrated for his groundbreaking work in the realm of technology. With a stellar track record of 11 patents to his name, he has significantly contributed to the fields of medicine and biotechnology.

Latest Patents:

1. Purine Inhibitors of Human Phosphatidylinositol 3-kinase Delta: Francesc's novel compounds of formula (I) serve as potent PI3K-delta inhibitors, offering promising therapeutic solutions for conditions such as inflammation, asthma, COPD, and cancer.

2. Tricyclic Compounds as Inhibitors of Mutant IDH Enzymes: His tricyclic compounds of formula (I) demonstrate efficacy as inhibitors of mutant IDH enzymes, showcasing potential applications in the treatment and prevention of cancers associated with these enzymes.

Career Highlights:

Francesc Xavier Fradera Llinas is a pivotal member of Merck Sharp & Dohme Corporation, where his innovative spirit and technical expertise have flourished. Through his dedication to research and development, he has significantly advanced the company's efforts in pioneering new pharmaceutical solutions.

Collaborations:

Francesc has collaborated closely with accomplished professionals in his field, including Michelle R Machacek and Stephane L Bogen. Together, they have synergized their skills and knowledge to push the boundaries of scientific discovery and drive forward groundbreaking projects.

Conclusion:

In conclusion, Francesc Xavier Fradera Llinas stands as a trailblazer in the world of technology and innovation. His relentless pursuit of excellence and unwavering commitment to pushing the boundaries of scientific possibility serve as an inspiration to aspiring inventors worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…